The stock of Terns Pharmaceuticals Inc (TERN) has gone down by -5.82% for the week, with a -31.23% drop in the past month and a -7.41% drop in the past quarter. The volatility ratio for the week is 5.25%, and the volatility levels for the past 30 days are 8.02% for TERN. The simple moving average for the past 20 days is -13.36% for TERN’s stock, with a 10.65% simple moving average for the past 200 days.
Is It Worth Investing in Terns Pharmaceuticals Inc (NASDAQ: TERN) Right Now?
Additionally, the 36-month beta value for TERN is -0.37. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TERN is 59.14M and currently, short sellers hold a 6.36% ratio of that float. The average trading volume of TERN on October 09, 2024 was 1.91M shares.
TERN) stock’s latest price update
Terns Pharmaceuticals Inc (NASDAQ: TERN)’s stock price has dropped by -1.12 in relation to previous closing price of 7.81. Nevertheless, the company has seen a loss of -5.82% in its stock price over the last five trading days. globenewswire.com reported 2024-10-07 that FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee’s acceptance of employment with Terns.
Analysts’ Opinion of TERN
Many brokerage firms have already submitted their reports for TERN stocks, with Mizuho repeating the rating for TERN by listing it as a “Buy.” The predicted price for TERN in the upcoming period, according to Mizuho is $16 based on the research report published on June 22, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see TERN reach a price target of $18. The rating they have provided for TERN stocks is “Buy” according to the report published on June 07th, 2023.
ROTH MKM gave a rating of “Buy” to TERN, setting the target price at $23 in the report published on May 31st of the previous year.
TERN Trading at -5.61% from the 50-Day Moving Average
After a stumble in the market that brought TERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.26% of loss for the given period.
Volatility was left at 8.02%, however, over the last 30 days, the volatility rate increased by 5.25%, as shares sank -28.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.65% lower at present.
During the last 5 trading sessions, TERN fell by -7.07%, which changed the moving average for the period of 200-days by +20.19% in comparison to the 20-day moving average, which settled at $8.91. In addition, Terns Pharmaceuticals Inc saw 18.99% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TERN starting from Lu Hongbo, who purchase 476,190 shares at the price of $10.50 back on Sep 12 ’24. After this action, Lu Hongbo now owns 476,190 shares of Terns Pharmaceuticals Inc, valued at $4,999,995 using the latest closing price.
Vignola Mark J., the Chief Financial Officer of Terns Pharmaceuticals Inc, sale 10,000 shares at $11.00 during a trade that took place back on Sep 10 ’24, which means that Vignola Mark J. is holding 91,940 shares at $110,000 based on the most recent closing price.
Stock Fundamentals for TERN
Current profitability levels for the company are sitting at:
- -81.86 for the present operating margin
- 0.31 for the gross margin
The net margin for Terns Pharmaceuticals Inc stands at -72.54. The total capital return value is set at -0.49. Equity return is now at value -38.92, with -36.84 for asset returns.
Based on Terns Pharmaceuticals Inc (TERN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -317.24. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -42.13.
Currently, EBITDA for the company is -102.27 million with net debt to EBITDA at 0.85. When we switch over and look at the enterprise to sales, we see a ratio of 437.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.02.
Conclusion
In conclusion, Terns Pharmaceuticals Inc (TERN) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
